RNA, U6 small nuclear 262, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-262P profile across patient tissues and cancer cell-line models. RNU6-262P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU6-262P is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, RNU6-262P RNA expression shows 9,135 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, COAD, and LAML as cancer lineages where RNU6-262P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-262P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-262P survival associations across molecular data types. RNU6-262P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-262P RNA expression–survival associations across cancer types. High RNU6-262P expression shows unfavorable associations in MESO, KIRC, CHOL, KIRP and DLBC, but favorable associations in LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNU6-262P RNA expression.
This table summarizes RNU6-262P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-262P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-262P shows lower tumor expression in UCEC and higher tumor expression in COAD and STAD. The COAD box plot shows higher RNU6-262P RNA expression in tumor versus normal tissue (log2 FC = +0.162, t-test p = .026).
This table shows molecular features associated with RNU6-262P in patient tissues and cancer cell lines. In patient samples, RNU6-262P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
